Related Posts


.jpg?width=450&height=250&name=Doctors-and-the-Virtual-Medical-Revolution-and-Technological-Advances-Artificial-Intelligence-(AI).jpg)
You are about to leave Risk Strategies website and view the content of an external website.
You are leaving risk-strategies.com
By accessing this link, you will be leaving Risk Strategies website and entering a website hosted by another party. Please be advised that you will no longer be subject to, or under the protection of, the privacy and security policies of Risk Strategies website. We encourage you to read and evaluate the privacy and security policies of the site you are entering, which may be different than those of Risk Strategies.
Summary: Due to recent federal changes, COVID-19 vaccine access rules now vary by state, with prescriptions required in several states. Employers should prepare for varying access and future supply challenges. Key considerations for employers sponsoring group health plans include:
Read on for more information regarding these recent changes and what to expect next.
As the U.S. moves into the 2025–2026 season, the policy landscape around COVID-19 vaccine recommendations is shifting. For much of the COVID-19 pandemic, federal emergency authority simplified access and ensured that employees could walk into a pharmacy and receive a vaccine without barriers. That framework has now changed. This post explains how new rules may impact employee access, coverage, and potential costs for both self-funded and fully insured group health plans.
During the height of COVID-19, the federal government invoked the Public Readiness and Emergency Preparedness (PREP) Act. One of its key provisions granted pharmacists across the country the authority to administer COVID-19 vaccines to children and adults without a prescription. This measure was designed to maximize convenience, reduce bottlenecks, and make vaccines available in as many locations as possible.
That authority expired in 2024. In August 2025, the Food and Drug Administration (FDA) also narrowed the vaccine’s authorization, and revoked broad emergency use authorization. The updated vaccine is now authorized primarily for:
With these changes, states now have primary jurisdiction over who can prescribe and administer vaccines. Some states already had permanent laws empowering pharmacists to vaccinate adults with FDA-approved products, while others required standing orders from physicians or collaborative practice agreements. Without the federal umbrella, these differences now shape access state by state.
This is more than a technicality. In practice, it means that in certain states, employees can still walk into a pharmacy and receive the updated COVID-19 shot. In others, they must first secure a prescription from a healthcare provider. Beginning in September 2025, CVS indicated that a prescription would be required in select states, but the situation is changing rapidly. We found that at least some of those states have since issued standing orders, removing prescription requirements within their jurisdictions for all ages.
The re-emergence of state control has created a patchwork system impacting both employers and employees. As of September 20, 2025, based on our analysis of states’ rules:
This inconsistency means that a workforce spread across multiple states will face varying access, depending on where employees live. Employers with multistate operations need to prepare for potential uneven vaccination access rates and employee confusion, which can affect absenteeism, productivity, and employee perceptions.
Self-funded employer plan sponsors operating in states with prescription-only access who want to simplify access for their employees and their families may consider:
Fully insured employer plan sponsors might generally have fewer tools available, but they also can take steps to improve access for their employees, including:
On September 19, 2025, the ACIP met to update its federal recommendations for COVID-19 vaccination. The outcome left much of the ambiguity in place:
While the 2025–2026 season is unlikely to see major supply shortages, the longer-term outlook could be more challenging. In August 2025, the Department of Health and Human Services announced plans to end federal funding for mRNA vaccine development projects, cutting nearly 500 million dollars in support. This will likely reduce the number of updated vaccines available in future seasons. Combined with narrower FDA authorizations and uneven state rules, the U.S. may face limited supply and higher costs by 2026–2027.
For employer group health plan sponsors, this underscores the importance of planning ahead:
The U.S. is entering a new era of COVID-19 vaccine policy: federal direction has receded, and state rules now drive access. With ACIP stopping short of clear mandates, employers must prepare for uneven coverage and operational uncertainty in the near term, while also planning for potential supply and cost pressures in future seasons.
For group health plan sponsors, the focus should be on:
Employers that anticipate these shifts and plan proactively may be better positioned to protect their workforce and manage costs, even as the policy environment continues to evolve.
Risk Strategies Consulting can help your organization evaluate the right tools and partners to create a better experience for your employees. Learn more about Risk Strategies Consulting here.
The contents of this article are for general informational purposes only and Risk Strategies Company makes no representation or warranty of any kind, express or implied, regarding the accuracy or completeness of any information contained herein. Any recommendations contained herein are intended to provide insight based on currently available information for consideration and should be vetted against applicable legal and business needs before application to a specific client.